The univariate analysis revealed a significantly higher number of male individuals and individuals with diabetes mellitus, chronic kidney disease, ischemic heart disease, peripheral artery disease, and a higher Charlson comorbidity index among P2Y12 inhibitor users. This evidence concerns the gene P2RY12 and coronary artery disorder.